<DOC>
	<DOCNO>NCT00988208</DOCNO>
	<brief_summary>The purpose study determine whether lenalidomide safe effective use combination docetaxel prednisone treatment subject metastatic Castrate-Resistant Prostate Cancer . The addition lenalidomide docetaxel prednisone propose increase life expectancy subject .</brief_summary>
	<brief_title>Study Evaluate Safety Effectiveness Lenalidomide Combination With Docetaxel Prednisone Patients With Castrate-Resistant Prostate Cancer</brief_title>
	<detailed_description>In November 2011 , Data Monitoring Committee conclude unlikely study would meet primary endpoint overall survival ( OS ) recommend study stop . The study terminate accordance recommendation . All site instruct immediately discontinue patient experimental lenalidomide/placebo treatment administer either combination chemotherapy single agent follow chemotherapy discontinuation . Subsequently , Protocol Amendment 3 issue provide follow : To continue collect information Second Primary Malignancies ( SPMs ) additional treatment Prostate Cancer randomize subject survival follow-up . To continue provide docetaxel prednisone 10 cycle subject randomize non-US site ongoing CC-5013-PC-002 protocol decision make discontinue lenalidomide/placebo experience benefit per investigator discretion . For subject exceed 10 cycle docetaxel prednisone time Protocol Amendment 3 approval , additional two cycle provide . All reference dose study procedure pertain safety , efficacy , exploratory endpoint lenalidomide/placebo discontinue part Protocol Amendment 3 .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . Must sign Informed Consent Form ( ICF ) 2 . Males ≥ 18 year age 3 . Able adhere study visit schedule requirement protocol 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 5 . Life expectancy ≥ 12 week 6 . Willingness participate PatientReported Outcomes assessment 7 . Serum testosterone level &lt; 50 ng/dL 8 . Confirmed metastatic adenocarcinoma prostate unresponsive refractory hormonal therapy 9 . Have document disease progression receive follow hormonal therapy determine increase Serum Prostate Specific Antigen ( PSA ) level , Radiological Progression , ≥2 new bone lesion 10 . Subjects must agree receive counseling related pregnancy precaution , teratogenic risk lenalidomide 11 . Refrain donate blood semen define protocol 1 . A history clinically significant disease place subject unacceptable risk study entry 2 . Prior Therapy thalidomide , lenalidomide pomalidomide 3 . Prior chemotherapy prostate cancer 4 . Use experimental drug therapy within 28 day prior randomization 5 . Prior radiation ≥ 30 % bone marrow radiation therapy within 28 day prior randomization 6 . Prior use Strontium89 time Samarium153 within 56 day prior randomization 7 . Surgery within 28 day prior randomization 8 . Concurrent antiandrogen therapy 9 . Abnormal serum chemistry hematology laboratory value 10 . Significant active cardiac disease within previous 6 month : 11 . Thrombotic thromboembolic event within past 6 month : 12 . History peripheral neuropathy ≥grade 2 13 . History severe hypersensitivity reaction drug formulate polysorbate 80 14 . Paraplegia 15 . History Central nervous system ( CNS ) brain metastases 16 . History malignancy prostate cancer within past 5 year , exception treat basal cell/squamous cell carcinoma skin 17 . Concurrent use alternative cancer therapy</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Castrate-Resistant Prostate Cancer</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Lenalidomide</keyword>
</DOC>